论文部分内容阅读
绝大多数慢性髓系白血病(CML)和部分成人急性淋巴细胞白血病(ALL)存在Ph染包怵,即9号、22号染色体易位,t(9;22)(q34;q11)。该易位产生BCR-ABL嵌合基因,中表达BCR-ABL蛋白。后者具有酪氨酸激酶活性,引起细胞恶性转化。目前认为,高酪氨酸激酶活性在白血病发生发展中起关键作用。因此针对性地研究阻断BCR-ABL蛋白激酶表达和生物学活性的药物成为白血病治疗的热点课题。本文综述近年来酪氨酸激酶抑制剂治疗进展。
The vast majority of chronic myeloid leukemia (CML) and some adult acute lymphoblastic leukemia (ALL) have Ph staining thyroid infection, namely chromosome 9 and 22 chromosome translocation, t(9;22)(q34;q11). This translocation produces the BCR-ABL chimeric gene, which expresses the BCR-ABL protein. The latter has tyrosine kinase activity and causes malignant transformation of cells. It is currently believed that high tyrosine kinase activity plays a key role in the development of leukemia. Therefore, the targeted study of drugs that block the expression and biological activity of BCR-ABL protein kinases has become a hot topic in leukemia treatment. This article reviews recent advances in the treatment of tyrosine kinase inhibitors.